Medical diagnostics company Guardant Health has sued rival Natera in California federal court for allegedly stealing trade ...

The lawsuit claims Natera aggressively recruited bioinformatics scientists from Guardant to “jumpstart its lagging position ...

Delaware federal judge reverses jury verdict in CareDx’s favour | Natera’s patents covering organ transplant testing ...

Guardant Health is overcoming skepticism with new cancer tests. Learn why GH stock is a buy, with strong growth and a shift ...

Scotiabank raised the firm’s price target on Guardant Health (GH) to $52 from $47 and keeps an Outperform rating on the shares. Guardant Health ...

Guardant Health is a leader in liquid biopsy ... and Guardant commands the second-largest market share after the market leader Natera. Reveal’s differentiating feature is that it is "tumor ...

Guardant Health specializes in precision oncology, developing advanced blood tests for cancer detection and management. The core of its business lies in liquid biopsies for both advanced-stage and ...

Guardant Health (NYSE:GH) reported fourth-quarter adjusted EPS loss of 62 cents, compared to a loss of 64 cents a year ago, ...

Guardant Health, Inc. (NASDAQ:GH – Get Free Report)’s stock price traded down 6.9% on Friday following a weaker than expected ...

PALO ALTO, Calif. (AP) — PALO ALTO, Calif. (AP) — Guardant Health Inc. (GH) on Thursday reported a loss of $111 million in its fourth quarter. On a per-share basis, the Palo Alto, California ...

Guardant Health (NASDAQ:GH), a leader in precision oncology testing, announced its fourth-quarter results on Feb. 20. Total revenue rose 30% year over year to $201.8 million, outpacing analysts ...